

Name Index

H

Harman, D., 8
Hayflick, L., 4

M

Medawar, P., 4
Medvedev, Z., 5

O

Orgel, L., 13, 15

S

Szilard, L., 7

Y

Yamanaka, S., 68

Subject Index

A

- A β transport, 331, 332
Abnormal proteins, 18, 70
Accelerated aging, 7, 11, 12
Acetylcholine (ACh), 265, 266
Acetylcholine esterase (AChE), 265, 266, 269, 276, 281, 379
Active immunotherapy, 396–398, 403
Adenosine 3':5'-cyclic monophosphate (cAMP), 202, 265–268, 424
Adipose tissue, 40–42, 46, 201, 202
Adult neurogenesis, 244–248, 252, 382
Advanced glycation end products (AGEs), 16, 174, 213–215, 219, 332, 360
Age pigment, 79, 83
Age-associated memory impairment, 21
Aged mice, 19, 55, 71, 72, 280, 326, 365, 399
Age-related attentional deficit, 266
Age-related diseases, 4, 6, 9, 16–18, 20, 32
Age-related functional decline, 11, 16, 19
AGEs. *See* Advanced glycation end products (AGEs)
Aggregates, 18, 19, 97, 171, 172, 175–178, 315, 322, 329, 359, 365, 373, 396, 402, 419–426
Aging, 4–22, 32, 39, 42, 44–47, 51, 52, 55–57, 59, 68–72, 75, 79–86, 89–99, 101–103, 111–118, 171–178, 184, 191, 192, 199–202, 205, 210–220, 224, 232, 235, 244, 247, 248, 250–252, 257, 258, 263, 264, 267, 269, 276, 280, 282, 286, 292–301, 306, 311, 315, 326
Aging syndromes, 55, 58, 184, 191, 192
Alcainein, 311, 313–314
ALS. *See* Amyotrophic lateral sclerosis (ALS)
Alzheimer's disease (AD), 15, 17, 21, 171, 175, 176, 232, 306, 341, 342, 350, 358, 395
Amino acyl tRNA, 13, 14
Amnesia, 261
Amyloid, 17, 73, 171, 175, 176, 232, 266, 306, 320, 327, 332, 342, 344, 346, 348, 350, 359, 395–397, 400–404, 407
Amyloid β (A β), 266, 306, 320, 342
Amyloid β peptide, 311, 315
Amyloid β precursor protein, 306
Amyloidogenic pathway, 308, 396, 397
Amyloid precursor protein (APP), 73, 306–315, 320–323, 327, 329, 330, 332, 333, 359, 361–363, 367, 374, 379, 381, 396, 397, 400, 406
Amyloid-related imaging abnormalities (ARIA), 403–405, 407
Amyotrophic lateral sclerosis (ALS), 17, 71, 172, 177–178, 420
Anti-aging, 9, 93, 102, 202, 205
Antibody, 194, 218, 332, 346, 349, 396–408
Anti-dementia drug, 265, 266, 268, 269
Antigen presenting cells (APC), 398
Antioxidant, 9, 10, 12, 112, 113, 119, 204, 212, 219, 276, 345, 348, 358–362, 366, 369, 370, 372, 375, 376, 378–381, 383
Antioxidant response element (ARE), 204, 358, 364–374, 376, 381
Antioxidation enzyme, 119
APC. *See* Antigen presenting cells (APC)
Apolipoprotein, 74, 311, 346, 347
Apolipoprotein E4, 74
Apoptosis, 71, 116, 191, 212, 218, 219, 232, 234, 320, 345, 347, 348, 358, 359, 362–364, 367, 372, 373, 379

- APP. *See* Amyloid precursor protein (APP)
- ARE. *See* Antioxidant response element (ARE)
- ARIA. *See* Amyloid-related imaging abnormalities (ARIA)
- α -secretase, 308, 313, 379, 382, 396, 397
- α -synuclein, 17, 73, 171, 176, 420
- Attention, 13, 111, 112, 118, 203, 244, 258, 259, 262, 264, 315, 323, 324, 342, 346, 349, 358
- Autoimmune response, 406
- Autophagy, 18, 19, 84, 96, 97, 99, 100, 174, 177, 321, 329, 330, 359, 364–365, 372, 422, 423
- Axonal fasciculation, 84
- B**
- B cells, 231, 233, 396
- BACE. *See* β -site APP-cleaving enzyme (BACE)
- BACE1, 320–323, 383
- β -amyloid, 175, 358
- BchE. *See* Butyrylcholine esterase (BchE)
- Biomarkers, 39, 187, 342–351
- Blood-brain barriers, 330, 347, 403, 405, 406
- Brain aging, 84, 244, 250, 292–301, 307, 310, 314
- Brain development, 297
- BTB and CNC homology 1 (Bach1), 374–375
- β -site APP-cleaving enzyme (BACE), 308
- Budding yeast, 68, 90, 91, 93, 96, 99, 102
- Butyrylcholine esterase (BchE), 266
- C**
- Caenorhabditis elegans* (*C. elegans*), 94, 112–113, 115–117, 119, 172–178, 200, 201, 204, 258, 377, 381, 383
- CAG repeats, 418, 419, 421
- calorie restriction, 52
- Calorie restriction mimetics, 199–205
- cAMP. *See* Adenosine 3':5'-cyclic monophosphate (cAMP)
- cAMP response element binding protein (CREB), 202, 205, 266–267, 424
- cAMP-dependent protein kinase, 266
- Cancer, 4, 9, 31, 35, 36, 40, 51, 191, 201, 205, 224, 232–235
- Catalase, 10, 12, 112–114
- Catalytic disaggregation of A β deposition, 402
- Cataracts, 12, 55, 68, 69
- Cell death, 17, 69, 72, 81, 177, 220, 234, 330, 358, 359, 363, 364, 367, 372, 375, 376, 379–382
- Cell loss, 81, 92
- Cellular aging, 79, 80
- Cellular longevity, 90, 93, 94
- Cellular senescence, 55, 94, 96, 100, 211, 214, 219
- Centenarians, 32–47, 71
- Cerebellum, 263, 277–281, 286, 301, 326
- Cerebral cortex, 20, 80, 81, 379
- Cerebrospinal fluid (CSF), 184–186, 188, 228, 313, 314, 321, 330, 331, 342–345, 350, 360, 368, 369, 401, 404, 405, 407
- Chaperon, 15, 19
- Chaperon-mediated autophagy, 19
- Chemokines, 343, 346, 348, 361, 402
- Cholinergic hypothesis, 265, 266
- Chromatin remodeling, 54, 58
- Chronic kidney disease (CKD), 187, 192–193, 210–211, 213, 215–220
- Chronological aging, 5, 90, 92, 94–96
- Chronological life span (CLS), 91–93, 95–100, 102
- CKD. *See* Chronic kidney disease (CKD)
- clk-1*, 117, 125, 130–132, 140, 141, 148, 150, 126, 127
- Cockayne syndrome, 52, 68, 69
- Coffee, 377, 380–382
- Cognitive decline, 250, 264, 268, 292, 294, 323, 380, 396
- Cognitive function, 33–40, 42, 244, 258, 259, 264, 266–269, 276, 292, 296, 359, 382
- Cognitive impairment, 265–268, 326, 379, 381, 406
- Collagens, 4, 15, 16, 219, 231
- CREB. *See* cAMP response element binding protein (CREB)
- Colony-forming unit, 92
- Cross-linking, 8, 15
- CSF. *See* Cerebrospinal fluid (CSF)
- Cytokines, 38, 40, 202, 218, 327, 343, 346, 348, 361, 362, 365, 378, 382, 398
- Cytoplasm, 10, 11, 19, 113, 184, 192, 278, 309, 313, 422–425
- D**
- Database, 6, 44–46, 292, 301
- 3D culture, 74
- Declarative memory, 257, 261, 262, 264
- Dementia, 34–36, 73, 232, 247, 263–266, 268, 269, 292, 293, 301, 306, 307, 342–344, 349, 380, 395
- 2-deoxy-D-glucose (2DG), 12, 204

- Depression, 42, 43, 247, 249, 263–264, 343, 344, 350
- Diagnosis, 73, 292, 342, 344, 349–351
- Dietary restriction, 100, 174, 189
- Differentiation, 70, 73, 81, 83, 231, 233, 244–246, 249, 250, 323, 348, 362, 366, 372, 373
- Disease mechanisms, 67
- DNA damage, 52–59, 69, 71, 94, 99, 100
- DNA methylation, 20
- DNA polymerase, 14, 54, 55
- DNA repair, 7, 10, 52–55, 57, 58, 200, 347
- DNA replication, 14, 15, 55, 58, 423
- Donepezil, 265, 266, 268, 269
- E**
- Elderly humans, 72, 214
- Elderly patients, 70, 344
- Electron transport, 6, 11, 102, 114–118
- Endoplasmic reticulum (ER) stress, 215–220
- Energy expenditure, 10
- Energy metabolism, 20, 101, 112, 114, 117–119, 201–202
- Epigenetics, 19–21
- ER stress, 74, 211, 216–220, 329
- Error catastrophe, 13–16
- Exercise, 10–12, 20
- Extrachromosomal rDNA circle, 94
- F**
- F-actin, 84
- Family 1 β -glycosidase, 185, 193, 194
- FGF23, 185–189, 192–195
- Fibrils, 176, 320, 332, 396, 405, 407
- Fidelity, 13–15, 52
- FOXO, 173, 174, 200, 201, 205
- Frailty, 4, 5, 20, 32
- Free radical, 8–11, 89, 212, 375, 381, 402
- G**
- Galantamine, 265, 266
- gas-1*, 115, 117
- GCL
- γ -glutamylcysteine ligase (GCL)Gene expression, 6, 13, 15, 19, 20, 70, 71, 99–102, 118, 173, 187, 188, 266, 328, 347, 349, 367, 371, 421, 424
- Gene therapy, 327–328
- Genetic profiling, 349–250
- Genome-wide association study, 346, 349
- Genome-wide screening, 91, 172
- GGCX. *See* γ -glutamyl carboxylase (GGCX)
- γ -glutamyl carboxylase (GGCX), 226, 228–231, 233
- γ -glutamylcysteine ligase (GCL), 358, 359, 361, 364, 366–368, 373, 375–378, 383
- Ginseng, 377–380
- Ginsenoside, 378–380
- Glutathione (GSH), 10, 112, 114, 116, 279, 358, 361, 364, 366–368, 377, 378, 380, 381, 383
- Glutathione S-transferase (GST), 358, 359, 366, 368, 377, 378, 380, 381
- Glycation, 16, 211, 213–216
- Glycative stress, 211, 213–216, 218–220
- Glycogen synthase kinase-3 β (GSK-3 β), 374, 380
- Glyoxalase 1, 211, 214–215
- Gray matter, 292–301
- GSH. *See* Glutathione (GSH)
- GSK-3 β . *See* Glycogen synthase kinase-3 β (GSK-3 β)
- γ -secretase, 307–310, 313–315, 320–323, 359, 361, 362, 380, 396, 397
- GST. *See* Glutathione S-transferase (GST)
- H**
- Hair loss, 11, 55–57, 70
- Hayflick limit, 80
- HDAC. *See* Histone deacetylase (HDAC)
- HDAC3, 424–426
- Healthy longevity, 32, 37–45
- Heat stability, 16
- Hebbian theory, 262
- Heme oxygenase-1 (HO-1), 204, 358, 359, 363, 364, 366, 369, 374, 376–378, 380, 381, 383
- Heterochromatin markers, 70
- Heterochromatin protein, 58, 70, 93
- HGPS. *See* Hutchinson Gilford Progeria Syndrome (HGPS)
- Hippocampal neuron, 81, 82, 85, 373, 374, 382, 383
- Hippocampus, 20, 244–248, 250–252
- HiPSCs. *See* Human iPSCs (HiPSCs)
- Histone acetylation, 20, 21, 375, 424
- Histone deacetylase (HDAC), 21, 58, 93, 375, 424, 425
- Histone modifications, 20, 58
- H3K9me3, 54, 58, 70
- HO-1. *See* Heme oxygenase-1 (HO-1)
- H.M., 260, 261

- Homeostasis, 12, 15–19, 99, 100, 184, 187–189, 200–201, 204, 215–218, 249–250, 324, 329, 347, 361, 378, 383
- Hormesis, 10, 12, 203
- Human diploid fibroblasts, 79, 80, 83
- Human iPSCs (HiPSCs), 68–74
- Huntingtin, 171, 177, 421–424
- Huntington's disease (HD), 17, 172, 177, 419
- Hutchinson Gilford Progeria Syndrome (HGPS), 52, 56–59, 68–70, 73
- Hypermethylation, 20
- Hyperphosphorylation, 343, 366, 374, 381
- Hypertension, 35, 36, 210–212, 296, 297, 299, 301
- Hypoxia, 212–214, 216, 329, 378
- Hypoxia-inducible factor, 213
- I**
- ICER. *See* inducible cAMP early repressor (ICER)
- Immediate early gene (IEG), 266
- Immune response, 347, 348, 396, 398–400, 403
- In vitro* aging, 79, 80, 83
- Indoxyl sulfate, 212, 213, 216
- Induced pluripotent stem cell (iPSC), 68, 71, 72, 75
- Inducible cAMP early repressor (ICER), 267
- Inflammation, 37–40, 46, 72, 211, 213, 218, 227, 231, 348, 358, 361, 362, 367, 375, 382, 399, 401
- Insulin/IGF-1, 203
- Ionizing radiation, 7, 369
- iPSC. *See* Induced pluripotent stem cell (iPSC)
- Isoprostane, 9
- J**
- JNK-interacting protein 1 (JIP1), 307, 311, 312
- K**
- Kelch-like ECH-associated protein 1 (Keap1), 358, 359, 365, 370–372, 383
- Kidney aging, 210–215, 220
- kinesin, 311, 312, 315
- Klotho, 184–195, 211
- L**
- Lamin A (*LMNA*), 55–57, 70
- Learning, 21, 244, 245, 248, 258, 261, 262, 276, 278, 328, 366, 374, 375, 379, 382, 399–401
- Lifespan, 116, 4, 6, 7, 9–12, 22, 41, 45, 52, 56, 58, 79, 80, 83, 85, 86, 89, 91–95, 98, 100, 112–115, 117–119, 172, 184, 187, 199–202, 212, 213, 347
- Lifespan differences, 6
- Lipid peroxidation, 9, 16, 276, 360, 361, 369, 379, 381, 383
- Lipofuscin, 9, 79, 83, 116
- LMNA*. *See* Lamin A (*LMNA*)
- Longevity, 4, 10, 20, 32, 40–47, 83, 86, 89, 90, 94, 95, 98–100, 102, 173, 174, 199, 200, 203–205, 212, 267
- Longevity gene, 47, 99
- Long-term depression (LTD), 258, 263–264, 278, 280
- Long-term memory, 260
- Long-term potentiation (LTP), 258, 263, 264, 266, 276, 277, 280, 379
- LTD. *See* Long-term depression (LTD)
- LTP. *See* Long-term potentiation (LTP)
- Lysosome, 17, 19, 330, 364, 422
- M**
- Macroautophagy, 19
- Magnetic resonance imaging (MRI), 292, 297, 298, 301, 346, 349, 350, 403
- MAPK. *See* Mitogen-activated protein kinase (MAPK)
- Memory, 21, 73, 245, 248, 257–269, 276, 323, 328, 333, 341, 358, 359, 362, 363, 366, 374, 375, 378–382, 399–401
- Memory impairment, 20, 21, 261, 264, 265, 269, 358, 363, 374, 379–382
- Metabolic turnover, 13, 14, 17
- Methylglyoxal, 213–215, 219
- mev-1*, 115–118
- Microarray, 98, 100, 101, 351
- Microautophagy, 19
- Microglial-mediated phagocytosis, 402–404, 407
- Microhemorrhages, 403, 406, 407
- microRNA, 20, 21
- Mild cognitive impairment, 268, 323, 343, 360, 406
- Mineral homeostasis, 184–186
- Mini-mental state examination, 33, 35, 293, 347
- miRNAs, 21
- Misfolding, 14, 15, 17
- Mitochondria, 10–12, 70, 97, 102, 113–117, 119, 218, 329, 330, 363, 383, 424
- Mitochondrial DNA (mtDNA), 11, 12, 97, 115, 360
- Mitochondrial function, 12, 99, 100, 102

Mitochondrial metabolism, 71
 Mitogen-activated protein kinase (MAPK),
 373, 377, 379, 381
 Mitohormesis, 11, 12, 90, 98, 205
 Morris water maze, 268
 Mortality rate, 4, 6, 35
 MRI. *See* magnetic resonance imaging (MRI)
 mtDNA. *See* Mitochondrial DNA (mtDNA)
 Mutation frequency, 8, 15, 95
 Myelination, 246

N

Na⁺-K⁺-ATPase, 185, 186, 188, 189, 192, 194
 NAD(P)H
 quinone oxidoreductase 1, 358
 quinone oxidoreductase 1 (NQO1), 358,
 359, 361, 366, 369–370, 376–378, 381
 Natural aging, 68
 Nematode, 5, 6, 10, 12, 18, 22, 68, 112, 117,
 119, 172
 Neprilysin (NEP), 320, 323–328
 Neurodegeneration, 68, 69, 73, 172, 306, 323,
 326, 327, 329, 347, 418, 419, 426
 Neurodegenerative disease, 17–19, 21, 73, 85,
 171, 172, 175–178, 292, 294, 311, 313,
 315, 328, 329, 342, 344, 363, 367,
 417, 420
 Neurogenesis, 244–250, 323, 359, 365, 372,
 375, 396
 Neuroimaging, 292, 346, 349–350
 Neuroinflammation, 326, 333, 344, 348, 359,
 361–363, 366, 379, 406
 Neuronal aging, 70, 81–85
 Neuronal cell death, 284, 358, 360, 362–364,
 378, 381, 396, 406
 Neuronal plasticity, 85, 258, 259, 263, 264
 Neuro peptide Y (NPY), 200–202
 Neuroprotection, 83, 369
 NF-E2-related factor 2 (Nrf2), 204, 205,
 358–383
 Nitric oxide, 212, 278, 279, 285, 286, 358
 Nitric oxide (NO), 278, 285
 N-methyl-D-aspartate receptor
 (NMDA-R), 263
 Non-declarative memory, 261, 262
 Normal subject, 213
 NPY. *See* Neuro peptide Y (NPY)
 Nrf2. *See* NF-E2-related factor 2 (Nrf2)
 Nucleus, 15, 54, 92, 97, 201, 244, 265, 266,
 358, 373, 374, 422–426

O

Obesity, 40, 41, 202, 204, 301, 382
 Oligodendrogenesis, 244, 248–252
 Osteoarthritis, 232
 Osteoporosis, 4, 11, 55, 68, 230
 Oxidative damage, 10, 69, 90, 95, 111–113, 118,
 212, 276, 358–361, 365, 378–380, 383
 Oxidative stress, 6, 8, 10–12, 16, 18, 71, 72, 74,
 90, 95, 98, 112–114, 116, 204, 211–216,
 218–220, 276, 326, 329, 358–361, 368,
 369, 374, 376, 379, 381, 383, 396
 8-oxodG, 9

P

p3-Alc, 313, 314
 Parkinson disease (PD), 17, 21, 171, 176
 Passive immunotherapy, 401, 403
 PDE. *See* Phosphodiesterase (PDE)
 Peripheral sink, 332, 402, 404, 407
 Personality, 33, 42, 43, 46, 258, 269
 Personalized therapy, 71, 72, 74
 Pharmacological intervention, 264, 267
 Phosphatidylinositol-3-kinase (PI3K), 200,
 372–373, 376, 377, 380, 381
 Phosphodiesterase (PDE), 173, 267–269
 Physical function, 33, 44
 Physiological aging, 7, 17, 20, 55, 82
 Phytochemicals, 203, 358, 359, 363, 364,
 375–383
 PI3K. *See* Phosphatidylinositol-3-kinase (PI3K)
 PKA, cAMP-dependent protein kinase,
 266–267
 PKC. *See* Protein kinase C (PKC)
 Plaque, 37, 266, 329, 330, 332, 342, 348, 397,
 401, 406, 407
 Plasma, 40, 41, 92, 113, 186–188, 192, 193,
 308, 310, 347, 349, 360, 380, 396, 402,
 404, 405, 407
 Pluripotency marker, 69
 Polyglutamine, 172, 177, 417, 418, 420, 426
 Population doubling (PDL), 83
 Positron emission tomography, 346, 349
 Post-mitotic, 81, 83, 91, 103, 419, 422
 Post-mitotic cell, 8, 81, 91, 103, 422
 Prefrontal cortex, 249, 264
 Pregnane X receptor (PXR), 226, 230, 231,
 233, 235
 Premature aging, 11, 52, 55, 70, 184, 211, 212,
 219, 220
 Premature senescence, 68, 70, 211, 219

- Preventive medicine, 291
 Progeria, 52, 55–59, 68–70
 Progerin, 57, 58, 70
 Proliferation, 70, 92, 203, 227, 233, 245, 247–249, 362, 366–368, 372, 373
 Proofreading, 14
 Propidium iodide, 92
 Proteasome, 10, 18, 19, 101, 329, 371, 376, 422, 423, 426
 Protein aggregation, 172, 177, 178
 Protein conformation diseases, 17
 Protein degradation, 17, 18, 329, 422, 427
 Protein kinase C (PKC), 372, 382
 Protein misfolding, 14, 17, 329, 362, 376
 Protein phosphorylation, 101, 278
 Protein quality control, 329, 422, 423, 426
 Protein turnover, 18
 Proteostasis, 15–19, 99, 177, 178, 215–217, 329
 Purkinje cell (PCs), 263, 277, 284, 285
 PXR. *See* Pregnane X receptor (PXR)
- R**
- Rapamycin, 22, 96–98, 201, 204, 329
 Reactive carbonyl derivatives, 9
 Reactive oxygen species (ROS), 8, 10–12, 16, 21, 53, 69, 90, 98, 101, 111, 113–119, 205, 211, 212, 216, 218, 219, 224, 276, 279, 280, 282, 329, 330, 358, 359, 361, 364, 366, 367, 370, 373, 375, 379–381, 383
 Regenerative medicine, 68
 Replicative aging, 98, 100
 Replicative life span, 91–99
 Replicative senescence, 56, 79, 81, 101, 102
 Reproductive system, 124, 153, 155
 Retinal degeneration, 69
 Retinal vascular disorder, 403
 Ribosome, 13, 14, 96, 97, 101
 Rivastigmine, 266
 RNA polymerases, 15
 ROS. *See* Reactive oxygen species (ROS)
 Ryanodine receptor, 284–286
- S**
- SA β G. *See* Senescence-associated β -galactosidase (SA β G)
 SDHC, 115
 Senescence, 4, 5, 55, 58, 59, 68, 70, 80, 81, 85, 203, 211, 212, 214, 215, 219, 379
 Senescence-associated β -galactosidase (SA β G), 80, 82, 83, 219
 Sensory memory, 259, 260
 Sensory neurons, 142, 151–153
 Short-term memory, 260
 Signal transduction, 10, 185, 188, 194, 211, 216, 259, 262, 264, 266, 267, 269, 367, 372
sir2, 83, 90–97
 SIRT1, 83, 93, 201, 202, 204, 267, 424
 Sirtuin, 93, 96, 97, 203, 204, 267
 S-nitrosylation (S-nitrosation), 278
 SOD. *See* Superoxide dismutase (SOD)
 Sodium butylate, 21
 Soy isoflavones, 382–383
 Spatial memory, 245, 263
 Sporadic Alzheimer's disease, 306, 313–315, 321, 324
 Stem cell, 68, 69, 73, 74, 91, 245
 Steroid and xenobiotic receptor (SXR), 226, 230, 231, 233–235, 438
 Sulforaphane, 204, 373, 375–378
 Supercentenarians, 32, 43–46
 Superoxide dismutase (SOD), 9, 10, 98, 99, 112–114, 177, 348, 358, 360, 361, 366, 373, 377, 378, 380, 381
 Superoxide radical, 9, 212
 Surrogate marker, 342, 350
 Survival curve, 6, 7, 45, 93
 SXR. *See* Steroid and xenobiotic receptor (SXR)
 Synaptic plasticity, 250, 262, 263, 276–278, 281, 283, 285, 286
- T**
- T cells, 348, 396, 398, 400, 401, 405, 406
 Target of rapamycin (TOR), 21, 52, 96–98, 100, 201, 204
 Tau, 17, 74, 171, 175, 176, 342–345, 350, 359, 363, 365, 366, 368, 374, 380, 381, 396
 TDP-43, 172, 177, 420
 Telomere shortening, 56, 80
 Telomeres, 68, 69, 85
 Thiobarbituric acid reactive substances (TBARS), 9, 360
 Thiol modification, 370, 371
 Thromboemboli, 405, 407
 Topography, 244, 245–247
 Tor1, 90, 93, 96–99, 101
 TOR. *See* Target of rapamycin (TOR)
 Transcription, 13–15, 19, 43, 55, 98, 101, 102, 173, 174, 200, 205, 212, 216, 217, 230, 250, 266, 267, 347, 349, 358, 361, 362, 366, 367, 373, 376, 381, 383, 423, 424, 426
 Transgenic mice, 8, 12, 204, 327, 362, 369, 374, 380, 397, 399, 400, 402–404, 406

Translation, 13–15, 21, 52, 96, 97, 99, 217, 426
Transthyretin, 227, 228, 345, 347
Type II diabetes, 74

U

Ubiquitin, 18, 19, 54, 365, 371, 420, 422, 423
Ubiquitin proteasome, 422, 423
Ubiquitin proteasome system (UPS), 17–19,
422, 423
Unfolded protein response UPR, 216–219
Uremic toxin, 210–216, 219

V

Vaccines, 332, 399–401, 403–408
Vascular ageing, 70

Vasogenic edema, 403, 407
Vitamin C, 9
Vitamin E, 9, 113
Vitamin K, 224–226, 228–235

W

Werner syndrome (WS), 52, 68
White matter, 244, 249, 250, 293,
296–297, 301
White matter homeostasis, 244

X

X11-like, 311